IVUS 123 Essentials
IVUS optimizes PCI outcomes.1 Clinical data consistently shows the benefits of IVUS to determine treatment strategy, guide stent placement, and assess procedural results. We developed IVUS 123 Essentials in partnership with physicians to simplify IVUS workflow and help improve outcomes for patients.
Dr Jeremy Langrish explains the IVUS 123 methodology for every PCI procedure in less than 1 minute and 30 seconds.
IVUS 123 Methodology
Image interpretation resources
1. The SYNTAX II Trial studied the SYNERGY Bioabsorbable Polymer Stent in patients with either CTO or three vessel disease. The SYNTAX I trial studied the TAXUS Express2 drug eluting stent in patients with either Left Main or three vessel disease. Banning, Adrian, MBBS, MD. Clinical outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 5-year results of the SYNTAX II study. ESC Congress 2021.
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.